To conclude, HER2DX is a strong predictor of response to endocrine therapy in combination with dual HER2 blockade with trastuzumab-pertuzumab in HER2-positive/hormone receptor-positive early-stage breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.